Advanced formulations and nanotechnology-based approaches for pulmonary delivery of sildenafil: A scoping review.

Autor: Lazo REL; Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Federal University of Parana, Curitiba, 80210-170 Paraná, Brazil., Mengarda M; Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Federal University of Parana, Curitiba, 80210-170 Paraná, Brazil., Almeida SL; Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Federal University of Parana, Curitiba, 80210-170 Paraná, Brazil., Caldonazo A; Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Federal University of Parana, Curitiba, 80210-170 Paraná, Brazil., Espinoza JT; Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, State University of Ponta Grossa, Ponta Grossa, 84030-900 Paraná, Brazil., Murakami FS; Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Federal University of Parana, Curitiba, 80210-170 Paraná, Brazil. Electronic address: fsmurakami@gmail.com.
Jazyk: angličtina
Zdroj: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2022 Oct; Vol. 350, pp. 308-323. Date of Electronic Publication: 2022 Aug 26.
DOI: 10.1016/j.jconrel.2022.08.021
Abstrakt: Oral sildenafil (SDF) is used to treat pulmonary arterial hypertension (PAH), and its bioavailability is approximately 40%. Several formulations of nano and microparticles (for pulmonary delivery) are being developed because it is possible to improve characteristics such as release time, bioavailability, dose, frequency, and even directly target the drug to the lungs. This review summarizes the latest SDF drug delivery systems for PAH and explains challenges related to the development, the preclinical, and the clinical studies. A scoping review was conducted by searching electronic databases including PubMed, Scopus, and Web of Science to identify studies published between 2001 and 2021. From 300 articles found, 31 met the inclusion criteria. This review identified colloidal formulations such as polymeric, lipid, and metal-organic framework nanoparticles. Strategies were determined to reach the deep airways such as polymeric microparticles, large porous microparticles, nanocomposites, and nano in microparticles. Finally, aspects related to toxicological, pharmacokinetics, and gaps in information for potential use in humans were discussed. SDF formulations are significant candidates for the treatment of PAH by inhalation. In summation, future preclinical studies are still required in large animals, as there is no particular formulation yet submitted to clinical studies.
Competing Interests: Declaration of Competing Interest No potential conflict of interest was reported by the authors.
(Copyright © 2022 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: